Predictors of visceral leishmaniasis relapse in hiv-infected patients: A systematic review

PLoS Neglected Tropical Diseases

Volumn 5, Issue 6, 2011, Pages

  Cota, Gláucia F ^a,c   de Sousa, Marcos R ^b   Rabello, Ana ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c FUNDAÇÃO HOSPITALAR DO ESTADO DE MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY; MILTEFOSINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PENTAMIDINE ISETHIONATE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREDICTION; PROGNOSIS; RECURRENCE RISK; RELAPSE; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; SYSTEMATIC REVIEW; VIRUS TRANSMISSION; VISCERAL LEISHMANIASIS; CHEMOPROPHYLAXIS; IMMUNOLOGY; METHODOLOGY; RECURRENT DISEASE; REVIEW; RISK FACTOR;

ADULT; CD4 LYMPHOCYTE COUNT; CHEMOPREVENTION; FEMALE; HIV INFECTIONS; HUMANS; LEISHMANIASIS, VISCERAL; MALE; RECURRENCE; RISK FACTORS;

EID: 79959822382     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001153     Document Type: Article

References (75)

1. Desjeux P, Alvar J, (2003) Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 97 (Suppl 1): 3-15.
2. Desjeux P, Meert JP, Piot B, Alwar J, Medrano FJ, et al. (2000) Leishmania/HIV co-infection, South Western Europe 1990-98 Geneva World Health Organization Report No.:42.
3. Lopez-Velez R, Perez-Molina JA, Guerrero A, Baquero F, Villarrubia J, et al. (1998) Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg 58 (4): 436-43.
4. Gradoni L, Scalone A, Gramiccia M, Troiani M, (1996) Epidemiological surveillance of leishmaniasis in HIV-1-infected individuals in Italy. AIDS (London, England) 10 (7): 785-91.
5. Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, et al. (2008) The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21 (2): 334-59.
6. Sinha PK, Bimal S, Singh SK, Pandey K, Gangopadhyay DN, et al. (2006) Pre- & post-treatment evaluation of immunological features in Indian visceral leishmaniasis (VL) patients with HIV co-infection. Indian J Med Res 123: 197-202.
7. Olivier M, Badaro R, Medrano FJ, Moreno J, (2003) The pathogenesis of Leishmania/HIV co-infection: cellular and immunological mechanisms. Ann Trop Med Parasitol 97 (Suppl 1): 79-98.
8. Tremblay M, Olivier M, Bernier R, (1996) Leishmania and the pathogenesis of HIV infection. Parasitol Today 12 (7): 257-61.
9. Villanueva JL, Alarcon A, Bernabeu-Wittel M, Cordero E, Prados D, et al. (2000) Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 19 (10): 798-801.
10. Molina I, Falco V, Crespo M, Riera C, Ribera E, et al. (2007) Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 60 (4): 837-42.
11. Berenguer J, Cosin J, Miralles P, Lopez JC, Padilla B, (2000) Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS (London, England) 14 (18): 2946-8.
12. Casado JL, López-Velez R, Pintado V, Quereda C, Antela A, et al. (2001) Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy. Eur J Clin Microbiol Infect Dis 20 (3): 202-5.
13. Paredes R, Munoz J, Diaz I, Domingo P, Gurgui M, et al. (2003) Leishmaniasis in HIV infection. J Postgrad Med 49 (1): 39-9.
14. Sundar S, (2001) Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6 (11): 849-54.
15. Rabello A, Orsini M, Disch J, (2003) Leishmania/HIV co-infection in Brazil: an appraisal. Ann Trop Med Parasitol 97 (Suppl 1): 17-28.
16. World Health Organization (2009) Leishmaniasis: background information. A brief history of the disease. Available: www.who.int/leishmaniasis/en/. Accessed 2011 Feb 18.
17. Jimenez-Exposito MJ, Alonso-Villaverde C, Sarda P, Masana L, (1999) Visceral leishmaniasis in HIV-infected patients with non-detectable HIV-1 viral load after highly active antiretroviral therapy. AIDS (London, England) 13 (1): 152-3.
18. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6: e1000100.
19. Wilczynski NL, Haynes RB, (2004) Developing optimal search strategies for detecting clinically sound prognostic studies in MEDLINE: an analytic survey. BMC Med 2: 23-27.
20. Manchikanti L, Datta S, Smith HS, Hirsch JA, (2009) Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: part 6. Systematic reviews and meta-analyses of observational studies. Pain Physician 12 (5): 819-50.
21. Groenwold RH, Rovers MM, (2010) The Catch-22 of appraisals on the quality of observational studies. J Clin Epidemiol 63 (10): 1059-60.
22. Malta M, Cardoso LO, Bastos FI, Magnanini MM, da Silva CM, (2010) STROBE initiative: guidelines on reporting observational studies. Rev Saude Publica 44 (3): 559-65.
23. Cabie A, Matheron S, Lepretre A, Bouchaud O, Deluol AM, et al. (1992) Visceral leishmaniasis in HIV infection. A totally opportunistic infection. Presse Med 21 (35): 1658-62.
24. Peters BS, Fish D, Golden R, Evans DA, Bryceson AD, et al. (1990) Visceral leishmaniasis in HIV infection and AIDS: clinical features and response to therapy. Q J Med 77: 1101-11.
25. Altes J, Salas A, Riera M, Udina M, Galmes A, et al. (1991) Visceral leishmaniasis: another HIV-associated opportunistic infection? Report of eight cases and review of the literature. AIDS (London, England) 5 (2): 201-7.
26. Davidson RN, Di Martino L, Gradoni L, Giacchino R, Russo R, et al. (1994) Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 87 (2): 75-81.
27. Davidson RN, Russo R, (1994) Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B. Clin Infect Dis 19 (3): 560.
28. Rosenthal E, Marty P, Poizot-Martin I, Reynes J, Pratlong F, et al. (1995) Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans R Soc Trop Med Hyg 89 (2): 159-62.
29. Ramos A, Portero JL, Gazapo T, Yebra M, Portero F, et al. (1998) Visceral leishmaniasis in immunocompromised patients. An Med Interna 15 (6): 301-4.
30. Pintado V, López-Vélez R, (2001) HIV-associated visceral leishmaniasis. Clin Microbiol Infect 7 (6): 291-300.
31. Agostoni C, Dorigoni N, Malfitano A, Caggese L, Marchetti G, et al. (1998) Mediterranean leishmaniasis in HIV-infected patients: epidemiological, clinical, and diagnostic features of 22 cases. Infection 26 (2): 93-9.
32. Cruz I, Canavate C, Rubio JM, Morales MA, Chicharro C, et al. (2002) A nested polymerase chain reaction (Ln-PCR) for diagnosing and monitoring Leishmania infantum infection in patients co-infected with human immunodeficiency virus. Trans R Soc Trop Med Hyg 96 (Suppl 1): S185-9.
33. d'Ettorre G, Ceccarelli G, Carnevalini M, Forcina G, Zaffiri L, et al. (2006) Central role of interleukin-15 in human immunodeficiency virus (HIV)-infected patients with visceral leishmaniasis. Acta Trop 99 (1): 83-7.
34. Daher EF, Fonseca PP, Gerhard ES, Leitao TM, Silva Junior GB, (2009) Clinical and epidemiological features of visceral leishmaniasis and HIV co-infection in fifteen patients from Brazil. J Parasitol 95 (3): 652-5.
35. Hurissa Z, Gebre-Silassie S, Hailu W, Tefera T, Lalloo DG, et al. (2010) Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia. Trop Med Int Health 15 (7): 848-55.
36. Antinori S, Calattini S, Longhi E, Bestetti G, Piolini R, et al. (2007) Clinical use of polymerase chain reaction performed on peripheral blood and bone marrow samples for the diagnosis and monitoring of visceral leishmaniasis in HIV-infected and HIV-uninfected patients: a single-center, 8-year experience in Italy and review of the literature. Clin Infect Dis 44 (12): 1602-10.
37. Fernandez-Guerrero ML, Robles P, Rivas P, Mojer F, Muniz G, et al. (2004) Visceral leishmaniasis in immunocompromised patients with and without AIDS: a comparison of clinical features and prognosis. Acta Trop 90 (1): 11-6.
38. Russo R, Nigro L, Panarello G, Montineri A, (2003) Clinical survey of Leishmania/HIV co-infection in Catania, Italy: the impact of highly active antiretroviral therapy (HAART). Ann Trop Med Parasitol 97 (Suppl 1): 149-55.
39. Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, et al. (2001) Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 95 (6): 668-72.
40. Lachaud L, Dereure J, Chabbert E, Reynes J, Mauboussin JM, et al. (2000) Optimized PCR using patient blood samples for diagnosis and follow-up of visceral Leishmaniasis, with special reference to AIDS patients. J Clin Microbiol 38 (1): 236-40.
41. Tortajada C, Perez-Cuevas B, Moreno A, Martinez E, Mallolas J, et al. (2002) Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients. J Acquir Immune Defic Syndr 30 (3): 364-6.
42. Ribera E, Cucurull E, Ocana I, Vallespi T, Gasser I, et al. (1995) [Visceral leishmaniasis in patients with HIV infection]. Enferm Infecc Microbiol Clin 13 (2): 73-9.
43. Riera C, Fisa R, Lopez P, Ribera E, Carrio J, et al. (2004) Evaluation of a latex agglutination test (KAtex) for detection of Leishmania antigen in urine of patients with HIV-Leishmania coinfection: value in diagnosis and post-treatment follow-up. Eur J Clin Microbiol Infect Dis 23 (12): 899-904.
44. Riera C, Fisa R, Ribera E, Carrio J, Falco V, et al. (2005) Value of culture and nested polymerase chain reaction of blood in the prediction of relapses in patients co-infected with Leishmania and human immunodeficiency virus. Am J Trop Med Hyg 73 (6): 1012-5.
45. Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, et al. (2006) A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 43 (3): 357-64.
46. Ribera E, Ocana I, de Otero J, Cortes E, Gasser I, et al. (1996) Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med 100 (5): 496-501.
47. ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN, (2008) Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 46 (11): 1702-9.
48. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep1992 41 (RR-17): 1-19.
49. Bourgeois N, Lachaud L, Reynes J, Rouanet I, Mahamat A, et al. (2008) Long-term monitoring of visceral leishmaniasis in patients with AIDS: relapse risk factors, value of polymerase chain reaction, and potential impact on secondary prophylaxis. J Acquir Immune Defic Syndr 48 (1): 13-9.
50. Pintado VM-RP, Rivera ML, Moreno S, Bouza E, (2001) Visceral leishmaniasis in HIV-infected and non-HIV-infected patients: a comparative study. Medicine (Baltimore) 80: 54-73.
51. Pizzuto M, Piazza M, Senese D, Scalamogna C, Calattini S, et al. (2001) Role of PCR in diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type 1. J Clin Microbiol 39 (1): 357-361.
52. Pasquau F, Ena J, Sanchez R, Cuadrado JM, Amador C, et al. (2005) Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterranean region. Eur J Clin Microbiol Infect Dis 24 (6): 411-8.
53. Laguna F, Adrados M, Alvar J, Soriano V, Valencia ME, et al. (1997) Visceral leishmaniasis in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 16 (12): 898-903.
54. Fernandéz Cotarelo MJ, Abellan Martinez J, Guerra Vales JM, Martinez Sanchez P, Rodrigo Gomez De La Barcena M, et al. (2003) Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis 37 (7): 973-7.
55. Bossolasco S, Gaiera G, Olchini D, Gulletta M, Martello L, et al. (2003) Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol 41 (11): 5080-4.
56. López-Vélez R, Videla S, Marquez M, Boix V, Jimenez-Mejias ME, et al. (2004) Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 53 (3): 540-3.
57. Delgado Fernandéz M, Garcia Ordonez MA, Martos Perez F, Reguera Iglesias JM, Jimenez Onate F, et al. (1997) [The clinical and evolutional characteristics of visceral leishmaniasis in patients with HIV infection]. An Med Interna 14 (10): 506-10.
58. Mira JA, Corzo JE, Rivero A, Macias J, De Leon FL, et al. (2004) Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am J Trop Med Hyg 70 (3): 298-301.
59. Berman J, (2006) Visceral leishmaniasis in the New World & Africa. Indian J Med Res 123: 289-94.
60. Schilling S, Glaichenhaus N, (2001) T cells that react to the immunodominant Leishmania major LACK antigen prevent early dissemination of the parasite in susceptible BALB/c mice. Infect Immun 69 (2): 1212-4.
61. Lachaud L, Chabbert E, Dubessay P, Dereure J, Lamothe J, et al. (2002) Value of two PCR methods for the diagnosis of canine visceral leishmaniasis and the detection of asymptomatic carriers. Parasitology 125: 197-207.
62. López-Vélez R, Casado JL, Pintado V, (2001) Decline of a visceral leishmaniasis epidemic in HIV-infected patients after the introduction of highly active antiretroviral therapy (HAART). Clin Microbiol Infect 7 (7): 394-5.
63. Kemp M, Kurtzhals JA, Kharazmi A, Theander TG, (1993) Interferon-gamma and interleukin-4 in human Leishmania donovani infections. Immunol Cell Biol 71: 583-7.
64. Lehn M, Weiser WY, Engelhorn S, Gillis S, Remold HG, (1989) IL-4 inhibits H2O2 production and antileishmanial capacity of human cultured monocytes mediated by IFN-gamma. J Immunol 143 (9): 3020-4.
65. Zanussi S, Simonelli C, Bortolin MT, D'Andrea M, Crepaldi C, et al. (1999) Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART+IL-2. Clin Exp Immunol 116 (3): 486-92.
66. Mezzaroma I, Carlesimo M, Pinter E, Alario C, Sacco G, et al. (1999) Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease. AIDS (London, England) 13 (10): 1187-93.
67. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, et al. (2000) Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 30 (Suppl 1): S5-14.
68. del Giudice P, Mary-Krause M, Pradier C, Grabar S, Dellamonica P, et al. (2002) Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. J Infect Dis 186 (9): 1366-70.
69. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338 (13): 853-60.
70. Sinha PK, Pandey K, Bhattacharya SK, (2005) Diagnosis & management of Leishmania/HIV co-infection. Indian J Med Res 121: 407-414.
71. Soriano V, Dona C, Rodriguez-Rosado R, Barreiro P, Gonzalez-Lahoz J, (2000) Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS (London, England) 14 (4): 383-6.
72. Berhe N, Wolday D, Hailu A, Abraham Y, Ali A, et al. (1999) HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS (London, England) 13 (14): 1921-5.
73. Laguna F, López-Vélez R, Pulido F, Salas A, Torre-Cisneros J, et al. (1999) Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS (London, England) 13 (9): 1063-9.
74. Faraut-Gambarelli F, Piarroux R, Deniau M, Giusiano B, Marty P, et al. (1997) In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob Agents Chemother 41 (4): 827-30.
75. Carrio J, Riera C, Gallego M, Ribera E, Portus M, (2001) In vitro susceptibility of Leishmania infantum to meglumine antimoniate in isolates from repeated leishmaniasis episodes in HIV-coinfected patients. J Antimicrob Chemother 47 (1): 120-1.